In the clinical trials for diagnosis of mild and moderate cases of COVID 19 patients, an antiviral drug, Favipiravir, originally discovered by Fuji Pharma of Japan, has proven promising.
According to the official statement on Thursday, the pharmaceutical company Cipla is all set to introduce Favipiravir, which has been effective for the treatment of COVID-19 patients, developed by the Council of Science and Industrial Research (CSIR).
Using locally available chemicals CSIR-Indian Institute of Chemical Technology (CSIR-IICT) managed to come out with a cost-effective process, which then transferred to Cipla for manufacturing purpose.
“Cipla has scaled up the process in their manufacturing facility and approached DCGI (Drug Controller General of India) for permission to launch the product in India. Given that DCGI has given restricted emergency use for Favipiravir in the country, Cipla is now all set to launch the product to help patients suffering from COVID-19,” the statement said.
CSIR-IICR Director S Chandrashekhar said this new technology is very successful and inexpensive, which enables Cipla to manufacture large amounts of the Drugs in a short time span.